Results 171 to 180 of about 28,157 (212)

COVID-19 Geçiren, CoronaVac ve BNT162b2 Aşı olan Bireylerde Hümoral İmmün Yanıtın Değerlendirilmesi

, 2022
Nesrin Gareayaghi, Harika Öykü Dinç, Doğukan Özbey, Rüveyda Akçin, Ferhat Osman Daşdemir, Seher Akkus, Önder Yüksel Eryiğit, Bekir Kocazeybek   +7 more
openalex   +2 more sources

T and B cell responses following primary COVID-19 vaccination with CoronaVac and two heterologous BNT162b2 booster doses. [PDF]

mSphere
Wangteeraprasert A, Pongcharoen S, Ngoenkam J, Makanut S.   +3 more
europepmc   +1 more source

Systematic Review and Meta-Analysis of the Incidence of Myocarditis and Guillain-Barré Syndrome in Adolescents Receiving COVID-19 mRNA Vaccine. [PDF]

Cureus
Kumar C, Akhileshwar, Kumar Neeraj R, Hameed S, Husain N, Roy SS, Mohan L, Anantsaznam.   +7 more
europepmc   +1 more source

Immunogenicity and Safety of Half and Full Doses of Heterologous and Homologous COVID-19 Vaccine Boosters After Priming with ChAdOx1 in Adult Participants in Indonesia: A Single-Blinded Randomized Controlled Trial. [PDF]

Vaccines (Basel)
Putri ND, Zhafira AS, Wicaksana P, Satari HI, Fadlyana E, Safitri V, Nurlailah N, Putri ES, Putri N, Iriyani DS, Ulina YS, Aprilia F, Pratama E, Nethalia I, Yustisiana R, Aini EQ, Fajarani R, Susilo A, Karyanti MR, Prayitno A, Sukandar H, Watts E, Mazarakis N, Multihartina P, Setiawaty V, Pangesti KNA, Indrati AR, Sundoro J, Handayani DO, Kartasasmita CB, Hadinegoro SR, Mulholland K.   +31 more
europepmc   +1 more source

Immunologic and biophysical features of the BNT162b2 JN.1 and KP.2 adapted COVID-19 vaccines. [PDF]

Nat Commun
Chen W, Tompkins KR, Windsor IW, Martinez LT, Ramos M, Li W, Shrivastava S, Rajput S, Chang JS, Sahasrabudhe P, Fennell KF, McLellan TJ, West GM, Dizon KP, Yam A, Mitra S, Saha S, Sharaf D, McKeen AP, Cadima CI, Muik A, Swanson W, Munoz Moreno R, Mendoza Daroca P, Sahin U, Anderson AS, Wu H, Swanson KA, Modjarrad K.   +28 more
europepmc   +1 more source

T-cell Response Induced by the BNT162b2 COVID-19 Vaccine in Children. [PDF]

Open Forum Infect Dis
Vogler I, Renken S, Hilker R, Lui BG, Finlayson A, Gurtman A, Sabharwal C, Kitchin N, Lockhart S, Gruber WC, Jansen KU, Swanson KA, Türeci Ö, Şahin U.   +13 more
europepmc   +1 more source

Low reactogenicity and high tumour antigen expression from mRNA-LNPs with membrane-destabilizing zwitterionic lipids. [PDF]

Nat Biomed Eng
Zhao Y, Li R, Liu P, Wang J, Cui Y, Ma Y, Cao Z, Cui M, Luozhong S, Wagner E, Laflin A, Ding Y, Hu Y, Tian Z, Tang C, Cai S, Young H, Liu D, Gu W, Bailey S, Jiang S.   +20 more
europepmc   +1 more source

Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls [PDF]

Tali Eviatar, A Pappo, Tal Freund, Yishai Friedlander, Ori Elkayam, David Hagin, Merav Heshin‐Bekenstein   +6 more
openalex   +1 more source

A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity. [PDF]

Front Immunol
Etna MP, Fuoco C, Severa M, Ricci D, Sinigaglia A, Lucca C, Cairo G, Bottazzi B, Garlanda C, Palamara AT, Barzon L, Gargioli C, Coccia EM.   +12 more
europepmc   +1 more source

Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination. [PDF]

J Diabetes Metab Disord
Van Baal L, Tan S, Fuhrer D, Reinold J, Dittmer U, Fiedler M.   +5 more
europepmc   +1 more source